Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)

Amylyx Pharmaceuticals (AMLX) has 4 years of EBT Margin data on record, last reported at 140.71% in Q4 2024.

  • For Q4 2024, EBT Margin rose 13662.0% year-over-year to 140.71%; the TTM value through Sep 2025 reached 556.63%, up 68734.0%, while the annual FY2024 figure was 345.26%, 35898.0% down from the prior year.
  • EBT Margin reached 140.71% in Q4 2024 per AMLX's latest filing, up from 17476.92% in the prior quarter.
  • Across five years, EBT Margin topped out at 140.71% in Q4 2024 and bottomed at 17476.92% in Q3 2024.
  • Average EBT Margin over 4 years is 3880.83%, with a median of 133.74% recorded in 2024.
  • Peak YoY movement for EBT Margin: surged 987530bps in 2023, then tumbled -1750194bps in 2024.
  • A 4-year view of EBT Margin shows it stood at 8120.0% in 2021, then skyrocketed by 98bps to 197.52% in 2022, then surged by 102bps to 4.1% in 2023, then surged by 3335bps to 140.71% in 2024.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 140.71% in Q4 2024, 17476.92% in Q3 2024, and 7106.55% in Q2 2024.